Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis. Additional opportunities with ASK1 inhibitors include cardiac, immunological and neurodegenerative indications.
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | Life Scien... | lifescienc... |
| - | BioRock Ve... | biorockven... |
Mentions in press and media 2
| Date | Title | Description | Source |
| 23.06.2021 | Seal Rock Therapeutics Announces Initiation of Phase 1 Clini... | SEATTLE, June 23, 2021 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage biotechnolog... | prnewswire... |
| 02.11.2020 | Seal Rock Therapeutics Announces Upcoming Presentations at A... | SEATTLE, Nov. 2, 2020 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a preclinical stage company de... | prnewswire... |